TJ Biopharma registers Phase 1 trial of CLDN6/4-1BB drug TJ037130
The China-based sponsor joins a field of at least 28 direct CLDN6-targeting programs, positioning a bispecific against a target none has yet advanced past Phase 1.
Executive Summary
- TJ Biopharma has registered a Phase 1 dose-escalation study testing a CLDN6/4-1BB bispecific in patients with advanced tumors who have exhausted standard treatment options.
- The trial enters a CLDN6-targeting field with dozens of direct comparators spanning antibodies, bispecifics, antibody-drug conjugates and CAR-T constructs, none of which has moved past early-phase testing in this indication.
- Most CLDN6 programs pair the target with CD3 to redirect T cells or use it as an antibody-drug conjugate payload target; this trial instead pairs CLDN6 with a 4-1BB costimulatory agonist, a distinct mechanistic bet on tumor-localized immune activation rather than direct T-cell engagement.
- The primary endpoint is safety and tolerability, so the trial will establish whether the combination is tolerable before any efficacy signal can be assessed.
The registration
TJ Biopharma Co., Ltd. added a new Phase 1 study to ClinicalTrials.gov on July 20, 2026, registering TJ037130 for adults with advanced or metastatic tumors confirmed positive for Claudin 6 (CLDN6) by immunohistochemistry. The trial plans to enroll 128 patients across sites in China, with dosing starting August 21, 2026, and a primary completion date of June 30, 2028. Eligible patients must have exhausted standard therapy options and cannot have received prior CLDN6-targeted therapy or 4-1BB agonists. NCT07715747A Phase I Study to Evaluate the Safety,Pharmacokinetics,Pharmacodynamics,and Efficacy of TJ037130 in Adult Participants With Advanced Solid TumorsNCT07715747
The design
The trial is open-label, single-arm, and not registrational. Its primary endpoint is the incidence, type, severity and treatment correlation of adverse events through 90 days after the last dose, with pharmacokinetic parameters (AUC and Cmax) tracked as secondary measures. That endpoint structure marks this as a safety and dose-finding study: it will establish whether the CLDN6/4-1BB combination is tolerable in patients, not whether it produces tumor responses. NCT07715747A Phase I Study to Evaluate the Safety,Pharmacokinetics,Pharmacodynamics,and Efficacy of TJ037130 in Adult Participants With Advanced Solid TumorsNCT07715747
The competitive field
CLDN6 has drawn direct comparators from BioNTech, Genmab, Astellas, Xencor, Servier, Numab Therapeutics, BeOne Medicines and Regeneron, among others, spanning monoclonal antibodies, bispecific T-cell engagers, antibody-drug conjugates, an RNA-based approach (BioNTech's BNT142) and CAR-T cell therapy (BioNTech's CLDN6 CAR-T program). Across this field, the most advanced programs, including SUNHO's IBD0333, TORL Biotherapeutics' TORL-1-23, Qilu Pharmaceutical's QLS5132 and Genmab's GEN1042, have reached Phase 1/2 but none has progressed further. Of the two CLDN6 x tumor Phase 1 programs with recorded outcomes, one completed and one terminated, a 1-of-2 split too small to read as a rate. NCT07715747A Phase I Study to Evaluate the Safety,Pharmacokinetics,Pharmacodynamics,and Efficacy of TJ037130 in Adult Participants With Advanced Solid TumorsNCT07715747
The mechanistic bet
Most named CLDN6 programs redirect T cells through CD3 bispecifics or deliver a cytotoxic payload through an antibody-drug conjugate; TJ037130 instead couples CLDN6 targeting with a 4-1BB costimulatory agonist, an approach aimed at activating tumor-infiltrating immune cells locally rather than engaging T cells directly. That difference is the hypothesis the Phase 1 data will test: whether tumor-restricted 4-1BB activation produces a tolerability or activity profile distinct from the CD3-engager and ADC approaches that dominate the target class.
Sponsor context
TJ Biopharma has completed 9 of 12 globally tracked trials, with 3 terminated, and holds a broader 20-trial pipeline that includes 2 trials currently active, not recruiting, and 2 recruiting. This is the sponsor's only registered trial of TJ037130 to date. NCT07715747A Phase I Study to Evaluate the Safety,Pharmacokinetics,Pharmacodynamics,and Efficacy of TJ037130 in Adult Participants With Advanced Solid TumorsNCT07715747
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.